CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation, and systematic mastocytosis. Its product pipeline includes Nofazinlimab (CS 1003), a PD-1 antibody to treat patients with hepatocellular carcinoma. The company’s products also comprise CS1002, CS2009, CS2011, CS5007, CS5005, CS5008, CS5005-R, CS5006, and CS5009 for the treatment of solid tumors; CS5001 to treat solid tumors and hematologic malignancies; and CS2013 and CS2015 for the treatment of autoimmune diseases.